All News

Physiomics is pleased to announce that it has signed a substantial new contract with a major global pharmaceutical company. The programme of studies will begin immediately and take an estimated 9 months to reach a conclusion. Physiomics will determine the optimal dosing regimen of a new compound currently under development by this client. Read more....

Physiomics is pleased to announce that it has now launched its Drug Combinations and Regimens database. DrugCARD® collates curated publicly available pre-clinical and clinical drug regimen data into one easily searchable tool. It also contains further clinical data and analysis which is only available through the collaboration with Pharmacometrics. Read more....

Physiomics is pleased to announce that it has signed a collaboration agreement with the University of Oxford and the Oxford University Hospitals NHS trust to support the development of Physiomics’ flagship Virtual Tumour Clinical technology. Virtual Tumour Clinical is used to predict optimal clinical regimens for cancer trials. Physiomics has been seeking academic and industrial partners to help calibrate the model with key data obtained from...

Physiomics is pleased to announce that it is participating in the 2013 NCRI Cancer Conference, taking place at the BT Convention Centre, Liverpool, on 3-6 November 2013. Dr Eric Fernandez, Project Leader, will present details of the on-going development of the Virtual Tumour Clinical platform. The abstract ("Dosing and schedule optimization with Virtual Tumour Clinical ") No B60 will be presented in the "Diagnosis and...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a contract with a new speciality pharma customer, to investigate how one of its new candidate drugs shrinks tumours. Read more....

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a contract with its first large pharma customer to supply cardiac toxicity risk modelling services. Read more...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the 2013 Safety Pharmacology Society's  annual Meeting (SPS), taking place at the Congress Centre de Doelen, Rotterdam, Netherlands, on 16-19 September 2013. Dr Hitesh Mistry will present the latest modelling advances of the cardiac toxicity predictive platform developed at Physiomics. Read more...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it won the second poster prize at the NC3Rs and Society of Biology Symposium held in London on 19 June 2013. The NC3Rs is the National Centre for the Replacement, Refinement & Reduction of Animals in Research. read more ...